ICON Public Limited (NASDAQ:ICLR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of ICON Public Limited (NASDAQ:ICLR) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $304.27.

Several equities analysts have issued reports on ICLR shares. Truist Financial decreased their price target on shares of ICON Public from $363.00 to $295.00 and set a “buy” rating for the company in a research report on Monday, October 28th. TD Cowen dropped their price target on ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. Redburn Atlantic began coverage on shares of ICON Public in a research report on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective on the stock. The Goldman Sachs Group reduced their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating for the company in a research report on Friday, October 25th. Finally, JPMorgan Chase & Co. cut their price target on ICON Public from $375.00 to $280.00 and set an “overweight” rating for the company in a research note on Friday, October 25th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Motco raised its position in shares of ICON Public by 1.5% in the first quarter. Motco now owns 3,882 shares of the medical research company’s stock valued at $1,304,000 after purchasing an additional 59 shares during the period. SkyView Investment Advisors LLC bought a new stake in shares of ICON Public during the 1st quarter worth $1,021,000. EverSource Wealth Advisors LLC boosted its holdings in shares of ICON Public by 17.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 283 shares of the medical research company’s stock worth $95,000 after purchasing an additional 42 shares in the last quarter. GAMMA Investing LLC grew its position in ICON Public by 50.0% during the second quarter. GAMMA Investing LLC now owns 261 shares of the medical research company’s stock valued at $82,000 after acquiring an additional 87 shares during the last quarter. Finally, ORG Partners LLC bought a new position in shares of ICON Public during the 2nd quarter valued at $59,000. 95.61% of the stock is owned by institutional investors.

ICON Public Trading Down 5.2 %

Shares of ICLR stock opened at $189.64 on Wednesday. The stock’s fifty day moving average price is $267.03 and its two-hundred day moving average price is $301.32. The company has a market cap of $15.65 billion, a PE ratio of 21.14, a P/E/G ratio of 1.40 and a beta of 1.25. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. ICON Public has a fifty-two week low of $188.57 and a fifty-two week high of $347.72.

ICON Public (NASDAQ:ICLR) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a return on equity of 11.91% and a net margin of 9.00%. The company had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period in the previous year, the firm posted $3.10 EPS. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. Equities analysts predict that ICON Public will post 13.43 EPS for the current fiscal year.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.